相关实验视频

Updated: May 27, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

CircST6GALNAC6通过调节PRKN/HK1信号通路来抑制膀癌的糖解

Yali Zuo¹, Da Ren¹, Haiqing He¹

¹Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China.

Molecular carcinogenesis

|February 17, 2025

概括

循环RNAcircST6GALNAC6抑制了膀癌 (BCa) 细胞的糖解和增殖. 过度表达circST6GALNAC6通过调节FUS/PRKN/HK1通路来抑制瘤生长,提供了一个潜在的BCa治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生化学

背景情况:

膀癌 (BCa) 是一种侵袭性的恶性瘤.
氧化糖解是癌细胞的标志性特征,涉及增加葡萄糖消耗和乳酸生产.
了解BCa糖解的调节机制对于开发有效的治疗方法至关重要.

研究的目的:

研究circST6GALNAC6在调节膀癌中的糖解和扩散中的作用和机制.
阐明circST6GALNAC6发挥作用的分子途径.

主要方法:

用于摄入葡萄糖的流细胞计,用于乳酸和ATP检测的商业套件.
海马XF-96p 分析器用于细胞外酸化率,细胞增殖的殖民地形成试验.
在裸体小鼠中的RNA免疫沉降,共免疫沉降和异种移植瘤模型.

主要成果:

在BCa细胞中,circST6GALNAC6的表达减少.
过度表达circST6GALNAC6抑制了BCa细胞糖解和增殖.
circST6GALNAC6通过FUS.通过增强PRKNmRNA稳定性促进了PRKN介导的HK1降解.
通过PRKN的淘汰,扭转了circST6GALNAC6对糖解的抑制作用.
在体内,circST6GALNAC6过度表达抑制了瘤的生长.

结论:

circST6GALNAC6通过FUS/PRKN/HK1轴抑制膀癌的糖解和扩散.
circST6GALNAC6作为膀癌的新型治疗点具有前途.

关键词:

这就是FUS FUS.一个HK1一个HK1 膀癌:膀癌是一种癌症.圆圈ST6GALNAC6 的时间葡萄糖溶解是什么

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...